

DEC. 23, 2002 11:09AM ^{ASIDE THIS} JENKINS & WILSON

NO. 088 PTO/P. 6 (10-56)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | | | | | | | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------------------------------------------------------------------------------------------------------------------|---|--------------------|------------|-------------|------------|----------------------|-----------------|----------------|--|---------------|--|------------------------|-------------|
| Substitute for form 1449A/PTO | | <i>Persons are required to respond to a collection of information unless it contains a valid OMB control number.</i> | | | | | | | | | | | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | | | | | | | | | | | |
| Sheet | 1 | of | 1 | | | | | | | | | | | | |
| <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/750,609</td> </tr> <tr> <td>Filing Date</td> <td>12/28/2000</td> </tr> <tr> <td>First Named Inventor</td> <td>David Robertson</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>1242/27/2/2</td> </tr> </table> | | | | Application Number | 09/750,609 | Filing Date | 12/28/2000 | First Named Inventor | David Robertson | Group Art Unit | | Examiner Name | | Attorney Docket Number | 1242/27/2/2 |
| Application Number | 09/750,609 | | | | | | | | | | | | | | |
| Filing Date | 12/28/2000 | | | | | | | | | | | | | | |
| First Named Inventor | David Robertson | | | | | | | | | | | | | | |
| Group Art Unit | | | | | | | | | | | | | | | |
| Examiner Name | | | | | | | | | | | | | | | |
| Attorney Docket Number | 1242/27/2/2 | | | | | | | | | | | | | | |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

| | | | |
|-----------------------|-----------------------|--------------------|-----------------|
| Examiner Signature | <u>Prabha Chendum</u> | Date Considered | <u>12/28/07</u> |
|-----------------------|-----------------------|--------------------|-----------------|

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DEC. 23. 2002 11:10AM JENKINS & WILSON

Please type a plus sign (+) inside this box

NO. 088 P. 7
TO/SB 10-96Approved for use through 10/31/98. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--------------------------------------------------------------------------------------------------|---|------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 09/750,609 |
| Sheet | 1 | Filing Date | 12/28/2000 |
| | | First Named Inventor | David Robertson |
| | | Group Art Unit | |
| | | Examiner Name | |
| | | Attorney Docket Number | 1242/27/2/2 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|----------------------------------------------------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No.* | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| SPE | C1 | FLATTEM ET AL., "Identification of a Coding Mutation in the Norepinephrine Transporter Gene Which Predisposes a Family to Orthostatic Intolerance," Am. J. Human Genet., Vol. 65 (No. 4), p. A43, (1999). | X |
| | C2 | SHANNON, "Functional Polymorphism of the Norepinephrine Transporter (NET) Presenting as Mitral Valve Prolapse and Orthostatic Intolerance," Circulation, Vol. 110 (No. 18), p. I.195, (November 2, 1999). | X |
| | C3 | OWEN ET AL., "Norepinephrine Transporter Gene Polymorphism is not Associated with Susceptibility to Major Depression," Psychiatry Research, Vol. 87 (No. 1), p. 1-5, (1999). | X |
| | C4 | PACHOLCZYK ET AL., "Expression Cloning of a Cocaine and Antidepressant-Sensitive Human Noradrenaline Transporter," BioNature, p. 350-353, (March 28, 1991). | X |
| | C5 | PORZGEN ET AL., "Molecular Cloning and Organization of the Coding region of the Human Norepinephrine Transporter Gene," Biochem. Biophys. Res. Commun., Vol. 215 (No. 3), p. 1145-1150, (October 24, 1995). | X |
| | C6 | WANG ET AL., "Genetic Approaches to Studying Norepinephrine Function: Knockout of the Mouse Norepinephrine Transporter," Gene Biol. Psychiatry, p. 1124-1130, (1999). | X |
| | C7 | ANONYMOUS, "Gene Characterization Kits," In: Stratagene Catalog, p. 39, (1988). | X |
| | C8 | PCT International Search Report for PCT International Application No. PCT/US00/35491. | |
| | C9 | JORDAN ET AL., "Contrasting Actions of Pressor Agents in Severe Autonomic Failure," Am. J. Med., Vol. 105 (No. 2), p. 116-124, (1998). (Abstract only) | X |
| | C10 | CHOY ET AL., "Abnormalities of the QT Interval in Primary Disorders of Autonomic Failure," Am. Heart J., Vol. 136 (No. 4), p. 664-671, (1998). (Abstract only) | X |
| ↓ | C11 | JORDAN ET AL., "Contrasting Effects of Vasodilators on Blood Pressure and Sodium Balance in the Hypertension of Autonomic Failure," J. Am. Soc. Nephrol., Vol. 10 (No. 1), p. 35-42, (1999). (Abstract only) | X |

| | | | |
|--------------------|----------------|-----------------|----------|
| Examiner Signature | Babha Chunduru | Date Considered | 12/23/02 |
|--------------------|----------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DEC. 23, 2002 11:10AM JENKINS & WILSON

Please type or print clearly inside this box

NO. 088-TO/SE P. 8 (10-98)

Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--------------------------------------------------------------------------------------------------|---|------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 09/750,609 |
| Sheet | 2 | Filing Date | 12/28/2000 |
| | | First Named Inventor | David Robertson |
| | | Group Art Unit | |
| | | Examiner Name | |
| | | Attorney Docket Number | 1242/27/2/2 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | |
|----------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| <i>gk</i> | C12 | JACOB ET AL., "Effects of Standing on Cerebrovascular Resistance in patients with Idiopathic Orthostatic Intolerance," Am. J. Med., Vol. 106 (No. 1), p. 59-64, (1999). (Abstract only) |
| | C13 | GILMAN ET AL., "Consensus Statement on the Diagnosis of Multiple System Atrophy," J. Neurol. Sci., Vol. 163 (No. 1), p. 94-98, (February 1, 1999). (Abstract only) |
| | C14 | SHANNON ET AL., "Acute Effect of Ephedrine on 24-h Energy Balance," Clin. Sci. (Colch), Vol. 96 (No. 5), p. 483-491, (1999). (Abstract only) |
| | C15 | JACOB ET AL., "Abnormal Norepinephrine Clearance and Adrenergic Receptor Sensitivity in Idiopathic Orthostatic Intolerance," Circulation, Vol. 99 (No. 13), p. 1706-1712, (April 6, 1999). (Abstract only) |
| | C16 | ROBERTSON ET AL., "Neurally Mediated Syncope: Pathophysiology and Implications for Treatment," Am. J. Med. Sci., Vol. 317 (No. 2), p. 102-109, (1999). (Abstract only) |
| | C17 | AUSTIN ET AL., "Multiple System Atrophy: Clinical Presentation and Diagnosis," Tenn. Med., Vol. 92 (No. 2), p. 55-57, (1999). (Abstract only) |
| | C18 | FURLAN ET AL., "Chronic Orthostatic Intolerance: a Disorder with Discordant Cardiac and Vascular Sympathetic Control," Circulation, Vol. 98 (No. 20), p. 2154-2159, (November 17, 1998). (Abstract only) |
| | C19 | ROBERTSON, "Distribution and Observed Associations of Orthostatic Blood Pressure Changes in Elderly General Medicine Outpatients," Am. J. Med. Sci., Vol. 315 (No. 5), p. 287-295, (1998). (Abstract only) |
| | C20 | CASWELL, "Orthostatic Intolerance," NASA West Virginia Space Grant Consortium, (1997). |
| | C21 | "Chronic Orthostatic Intolerance (COI) Nerve Abnormality," Causes Disabling Rapid Heart Rate, Dizziness, Dallas, Texas, (November 17, 1998). |
| <i>↓</i> | C22 | NATIONAL DYSAUTONOMIA RESEARCH FOUNDATION, "Orthostatic Intolerance Syndromes," (1997). |

| | | | |
|--------------------|-----------------------|-----------------|----------|
| Examiner Signature | <i>Brathe Chendum</i> | Date Considered | 12/28/02 |
|--------------------|-----------------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.